Arcus Biosciences Stock Performance
| RCUS Stock | USD 8.94 0.13 1.43% |
The firm shows a Beta (market volatility) of 1.12, which signifies a somewhat significant risk relative to the market. Arcus Biosciences returns are very sensitive to returns on the market. As the market goes up or down, Arcus Biosciences is expected to follow. At this point, Arcus Biosciences has a negative expected return of -0.89%. Please make sure to confirm Arcus Biosciences' maximum drawdown, as well as the relationship between the daily balance of power and relative strength index , to decide if Arcus Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Arcus Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return (1.43) | Five Day Return (6.39) | Year To Date Return (40.91) | Ten Year Return (47.41) | All Time Return (47.41) |
1 | Disposition of 3594 shares by Goeltz Ii Robert C. of Arcus Biosciences at 15.0 subject to Rule 16b-3 | 12/31/2024 |
2 | Arcus Biosciences Many Important Oncology Catalysts Coming Up In 2025 - Seeking Alpha | 01/14/2025 |
3 | Acquisition by Juan Jaen of 200000 shares of Arcus Biosciences at 13.33 subject to Rule 16b-3 | 01/23/2025 |
4 | Acquisition by Goeltz Ii Robert C. of 150000 shares of Arcus Biosciences at 13.33 subject to Rule 16b-3 | 01/27/2025 |
5 | Insider Trading | 01/31/2025 |
6 | Arcus Biosciences, Inc. Given Average Recommendation of Buy by Brokerages | 02/19/2025 |
7 | Arcus Biosciences Inc Q4 2024 Everything You Need to Know Ahead of Earnings | 02/25/2025 |
8 | Arcus Biosciences Releases Earnings Results | 02/26/2025 |
9 | Terry Rosen Increases Stake in Arcus Biosciences Inc with Recent Share Purchase | 02/28/2025 |
10 | Little Excitement Around Arcus Biosciences, Inc.s Revenues As Shares Take 26 percent Pounding | 03/06/2025 |
11 | Cantor Fitzgerald Has Positive View of RCUS FY2025 Earnings | 03/13/2025 |
12 | Acquisition by Kathryn Falberg of 8400 shares of Arcus Biosciences subject to Rule 16b-3 | 03/14/2025 |
13 | Acquisition by Carolyn Tang of 26700 shares of Arcus Biosciences subject to Rule 16b-3 | 03/17/2025 |
| Begin Period Cash Flow | 130 M |
Arcus |
Arcus Biosciences Relative Risk vs. Return Landscape
If you would invest 1,596 in Arcus Biosciences on December 22, 2024 and sell it today you would lose (702.00) from holding Arcus Biosciences or give up 43.98% of portfolio value over 90 days. Arcus Biosciences is currently does not generate positive expected returns and assumes 3.6968% risk (volatility on return distribution) over the 90 days horizon. In different words, 33% of stocks are less volatile than Arcus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Arcus Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arcus Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Arcus Biosciences, and traders can use it to determine the average amount a Arcus Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2412
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RCUS |
Estimated Market Risk
| 3.7 actual daily | 33 67% of assets are more volatile |
Expected Return
| -0.89 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.24 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Arcus Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Arcus Biosciences by adding Arcus Biosciences to a well-diversified portfolio.
Arcus Biosciences Fundamentals Growth
Arcus Stock prices reflect investors' perceptions of the future prospects and financial health of Arcus Biosciences, and Arcus Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Arcus Stock performance.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (1.10) % | ||||
| Operating Margin | (3.96) % | ||||
| Current Valuation | 44.1 M | ||||
| Shares Outstanding | 105.84 M | ||||
| Price To Earning | 27.69 X | ||||
| Price To Book | 1.98 X | ||||
| Price To Sales | 3.72 X | ||||
| Revenue | 258 M | ||||
| Gross Profit | (190 M) | ||||
| EBITDA | (269 M) | ||||
| Net Income | (283 M) | ||||
| Cash And Equivalents | 1.05 B | ||||
| Cash Per Share | 14.48 X | ||||
| Total Debt | 48 M | ||||
| Debt To Equity | 0.17 % | ||||
| Current Ratio | 6.22 X | ||||
| Book Value Per Share | 5.26 X | ||||
| Cash Flow From Operations | (170 M) | ||||
| Earnings Per Share | (3.14) X | ||||
| Market Capitalization | 959.98 M | ||||
| Total Asset | 1.15 B | ||||
| Retained Earnings | (1.13 B) | ||||
| Working Capital | 790 M | ||||
About Arcus Biosciences Performance
Assessing Arcus Biosciences' fundamental ratios provides investors with valuable insights into Arcus Biosciences' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Arcus Biosciences is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -5.2 K | -5.4 K | |
| Return On Tangible Assets | (0.25) | (0.26) | |
| Return On Capital Employed | (0.36) | (0.37) | |
| Return On Assets | (0.25) | (0.26) | |
| Return On Equity | (0.58) | (0.61) |
Things to note about Arcus Biosciences performance evaluation
Checking the ongoing alerts about Arcus Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Arcus Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Arcus Biosciences generated a negative expected return over the last 90 days | |
| Arcus Biosciences has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 258 M. Net Loss for the year was (283 M) with loss before overhead, payroll, taxes, and interest of (190 M). | |
| Arcus Biosciences currently holds about 1.05 B in cash with (170 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.48, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Arcus Biosciences has a poor financial position based on the latest SEC disclosures | |
| Over 83.0% of the company shares are owned by institutional investors | |
| Latest headline from kalkinemedia.com: Acquisition by Carolyn Tang of 26700 shares of Arcus Biosciences subject to Rule 16b-3 |
- Analyzing Arcus Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Arcus Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Arcus Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Arcus Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Arcus Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Arcus Biosciences' stock. These opinions can provide insight into Arcus Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.